- Safety studies describe a specific group, product, dose and duration.
- Small trials can miss uncommon side effects.
- “No adverse effects reported” isn’t proof of safety.
- Contamination depends on the product, not the study.
Types of safety evidence
| Evidence type | Shows | For shilajit |
|---|---|---|
| Animal toxicology | Doses causing harm in animals | No significant toxicity at doses tested[1] |
| Short human trials | Common side effects over weeks or months | Reported as well tolerated[2][3] |
| Longer human trials | Effects over a year or more | One 48-week trial[4] |
| Real-world reporting | Rare and unexpected effects | Limited |
Why small trials miss things
If a side effect affects one person in a thousand, a trial of 60 people is very unlikely to see it. Most shilajit trials involved dozens of participants, so they can detect common effects but not uncommon ones. That doesn’t mean uncommon effects exist; it means the trials can’t rule them out. See sample size and shilajit studies.
Who was studied
Trials mostly enrolled healthy adults, often excluding people with medical conditions, on regular medicines, or who were pregnant. Safety in those groups is therefore unknown, which is why we advise checking with a pharmacist or doctor first; see existing conditions and interactions.
“No side effects reported” isn’t proof
When a trial reports no adverse effects, it means none were recorded in that group, in that time, using that method of recording. It depends on how carefully side effects were looked for. Some studies record side effects systematically; others rely on participants mentioning them. Read “no side effects” as encouraging but limited.
The product question
Most shilajit trials used one purified, standardised extract.[2][3] Their safety findings describe that extract, which was presumably well characterised. A different product, made from different raw material, could have a different contaminant profile. That is why product safety depends on batch testing as well as on published studies; see why contaminant testing matters.
How to read a safety claim
- Who was studied?Healthy adults, older people, people with conditions?
- How many, and for how long?Dozens for weeks, or hundreds for years?
- Which product and dose?Is it the one you are considering?
- How were side effects recorded?Systematically or by self-report?
How we describe shilajit’s safety
Taken together, animal toxicology and small human trials of up to 48 weeks suggest shilajit is generally well tolerated in healthy adults when the product is clean. Long-term, rare and population-specific effects aren’t well characterised. That is why our safety pages combine “generally well tolerated” with clear advice about testing, the label serving and who should seek advice first; see Is shilajit safe? What we actually know.
How side effects are recorded
Better trials record side effects systematically: they ask participants at set points, use standard checklists, and report how many people in each group stopped early and why. Less rigorous studies may only note effects that participants volunteer. When reading a safety claim, look for how side effects were collected, not just whether any were reported.
Why real-world reporting matters
Once many people use a product, rare effects become visible through reports from doctors, pharmacists and the public. For supplements, reporting is patchy, so real-world safety signals for shilajit are limited. Reporting suspected reactions through the MHRA Yellow Card scheme or to the Food Standards Agency helps build that picture.[5]
Putting it into practice
When you read that shilajit is “clinically shown to be safe”, ask who took part, for how long, with which product, and how side effects were recorded. Then check your own product’s batch report, because study safety and product safety are separate questions.
Safety studies and the label
Label servings are usually designed with the available research in mind, but most products use different materials from those studied. Staying within the label serving keeps you closest to the range that has some safety data behind it. Taking more moves you further from anything that has been studied, and increases exposure to any contaminants in the batch. There is simply no evidence base for amounts well above the label, so staying within it is the safest choice you can make.
The bottom line
A safety study answers a narrow question about a particular group, product, dose and duration. Shilajit’s safety studies are reassuring within those limits but don’t prove safety for everyone or for every product. Combine the published evidence with batch testing and sensible use.
Frequently asked questions
What can a safety study tell you?
Whether harm appeared in a specific group, with a specific product, dose and duration.
Do shilajit studies prove it is safe?
They are reassuring within their limits but can’t prove safety for everyone or every product.
Why might small trials miss side effects?
Uncommon effects are unlikely to appear in a few dozen participants.
What does “no adverse effects reported” mean?
That none were recorded in that group and time; it depends on how carefully they were looked for.
Were people with health conditions included in trials?
Mostly not, so safety in those groups is unknown.
Does trial safety apply to my product?
Not automatically. Trials used a specific extract; check your product’s batch report.
How long have shilajit safety studies lasted?
What would strengthen safety evidence?
Larger, longer trials including older adults and people on medicines, plus real-world reporting.
Sources & further reading
Primary research, regulators and standards bodies are cited first. A source being listed here does not mean it supports every claim made by sellers; it supports the specific statement it is attached to.
- Asian Pacific Journal of Tropical Biomedicine authors. Evaluation of safety profile of black shilajit after 91 days repeated administration in rats. Asian Pacific Journal of Tropical Biomedicine, 2012. View source (opens in a new tab) [Animal safety study]
- Pandit S, Biswas S, Jana U, De RK, Mukhopadhyay SC, Biswas TK. Clinical evaluation of purified Shilajit on testosterone levels in healthy volunteers. Andrologia 48(5):570–575, 2016. PMID 26395129. View source (opens in a new tab) [Randomised controlled trial]
- Keller JL, Housh TJ, Hill EC, Smith CM, Schmidt RJ, Johnson GO. The effects of Shilajit supplementation on fatigue-induced decreases in muscular strength and serum hydroxyproline levels. Journal of the International Society of Sports Nutrition 16:3, 2019. doi:10.1186/s12970-019-0270-2; PMID 30728074. View source (opens in a new tab) [Randomised controlled trial]
- Pingali U, Nutalapati C. Shilajit extract reduces oxidative stress, inflammation, and bone loss to dose-dependently preserve bone mineral density in postmenopausal women with osteopenia: a randomized, double-blind, placebo-controlled trial. Phytomedicine 105:154334, 2022. doi:10.1016/j.phymed.2022.154334; PMID 35933897. View source (opens in a new tab) [Randomised controlled trial]
- Food Standards Agency. How to report a food safety or hygiene issue for members of the public. GOV.UK, 2026. View source (opens in a new tab) [Regulator guidance]